5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) – Pipeline Review, H2 2017’, provides in depth analysis on 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Central Nervous System, Cardiovascular and Metabolic Disorders under development targeting 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6)

The report reviews 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics and enlists all their major and minor projects

The report assesses 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Acorda Therapeutics Inc

Adamed Sp z oo

Avineuro Pharmaceuticals Inc

Axovant Sciences Ltd

Celon Pharma SA

Galenea Corp

H. Lundbeck A/S

Reviva Pharmaceuticals Inc

Suven Life Sciences Ltd

Teva Pharmaceutical Industries Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Overview

5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Companies Involved in Therapeutics Development

Acorda Therapeutics Inc

Adamed Sp z oo

Avineuro Pharmaceuticals Inc

Axovant Sciences Ltd

Celon Pharma SA

Galenea Corp

H. Lundbeck A/S

Reviva Pharmaceuticals Inc

Suven Life Sciences Ltd

Teva Pharmaceutical Industries Ltd

5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Drug Profiles

ADN-1184 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ADN-2013 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ADN-3662 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AV-3208 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AVN-0189 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AVN-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AVN-211 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AVN-3085 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AVN-3205 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AVN-322 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AVN-492 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

intepirdine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

landipirdine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LuAF-35700 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RP-5063 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule 1 to Antagonize 5-HT6 Receptor for CNS Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule 2 to Antagonize 5-HT6 for CNS Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize 5-HT 6 and 5-HT2A for Behavioral and Psychological Symptoms of Dementia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize 5-HT6 for Alzheimer's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize 5-HT6 Receptor for Mood Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Target 5-HT2C and 5-HT6 Receptor for Schizophrenia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SUVN-501 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SUVN-502 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SUVN-507 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SUVN-512 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Dormant Products

5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Discontinued Products

5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Product Development Milestones

Featured News & Press Releases

Oct 17, 2017: Reviva Pharmaceuticals Announces Successful Completion of Pre-IND Meeting With FDA on RP5063 for the Treatment of Pulmonary Arterial Hypertension

Sep 26, 2017: Axovant Announces Negative Topline Results of Intepirdine Phase 3 MINDSET Trial in Alzheimer's Disease

Sep 26, 2017: Set-back for Alzheimer’s drug in final stage trial

Jul 19, 2017: New Preclinical Data for Intepirdine Suggests Potential Neuroprotective Properties

Dec 09, 2016: Axovant Sciences Unveils New Data Analysis Showing Addition of Intepirdine to Standard Therapy May Help People with Alzheimer's Disease Maintain Independence Longer

Dec 09, 2016: Axovant Unveils New Data Analysis Showing Addition of Intepirdine to Standard Therapy May Help People with Alzheimer’s Disease Maintain Independence Longer

Dec 05, 2016: Axovant Sciences to Present Patient Function and Independence Data Analyses from Phase 2b Study of Investigational Treatment Intepirdine in Alzheimer’s Disease at CTAD 2016

Dec 05, 2016: Axovant to Present Patient Function and Independence Data Analyses from Phase 2b Study of Investigational Treatment Intepirdine in Alzheimers Disease at CTAD 2016

Nov 17, 2016: Reviva Pharmaceuticals Receives FDA Orphan Designation for Pulmonary Arterial Hypertension (PAH)

Sep 26, 2016: Axovant Sciences Receives FDA Fast-Track Designation for Intepirdine as an Investigational Treatment for Dementia with Lewy Bodies

Jul 18, 2016: Axovant Sciences Announces Presentations on Intepirdine and Sponsored Symposium at the 2016 Alzheimers Association International Conference

May 19, 2016: Reviva Pharmaceuticals Presented RP5063 Preclinical Efficacy Results for Pulmonary Arterial Hypertension at the American Thoracic Society Conference 2016

Apr 21, 2016: FAU site for first US clinical trial for Lewy Body dementia

Mar 11, 2016: Lundbeck starts clinical phase III program with Lu AF35700 in patients with treatment resistant schizophrenia

Feb 09, 2016: Axovant Sciences Announces Launch Of First-In-Class Clinical Programs Of RVT-101 For Lewy Body Dementia

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Indications, H2 2017

Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Number of Products under Investigation by Universities/Institutes, H2 2017

Products under Investigation by Universities/Institutes, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Pipeline by Acorda Therapeutics Inc, H2 2017

Pipeline by Adamed Sp z oo, H2 2017

Pipeline by Avineuro Pharmaceuticals Inc, H2 2017

Pipeline by Axovant Sciences Ltd, H2 2017

Pipeline by Celon Pharma SA, H2 2017

Pipeline by Galenea Corp, H2 2017

Pipeline by H. Lundbeck A/S, H2 2017

Pipeline by Reviva Pharmaceuticals Inc, H2 2017

Pipeline by Suven Life Sciences Ltd, H2 2017

Pipeline by Teva Pharmaceutical Industries Ltd, H2 2017

Dormant Products, H2 2017

Dormant Products, H2 2017 (Contd..1), H2 2017

Dormant Products, H2 2017 (Contd..2), H2 2017

Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Top 10 Indications, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports